Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

July 31, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

Vaccine PvCS N+C+R

Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6

BIOLOGICAL

Vaccine PvCS N+C

Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0

BIOLOGICAL

SSN Montanide ISA-51

SSN Montanide ISA-51 1 mL

Trial Locations (1)

Unknown

Malaria Vaccine and Drug Development Center, Santiago de Cali

All Listed Sponsors
collaborator

The Administrative Department of Science, Technology and Innovation, Colciencias

OTHER

lead

Malaria Vaccine and Drug Development Center

OTHER

NCT02083068 - Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax | Biotech Hunter | Biotech Hunter